Support Tool for Antibiotic Allergy deLabeling

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversitaire Ziekenhuizen KU Leuven

About this trial

Antibiotic allergy labels (AAL) are reported in 7% of inpatient's charts, especially for beta-lactams (86% of AAL, i.e., prevalence of 6%). They are associated with increased length of hospital stay, and use of second-line and broad-spectrum antibiotics. Allergy workups are able to invalidate the majority of these AAL but are time-consuming and require invasive skin and provocation testing. The investigators recently evaluated, for the first time in Europa, a strictly non-invasive delabeling protocol using a questionnaire, medical file search and contact with primary care health care workers in 200 adult internal medicine inpatients with a beta-lactam AAL. Up to half of the AAL could be removed or refined, demonstrating the potential of this strategy. In this project, they aim to assess the impact of using the non-invasive 'AAL-fact-check' tool in a multicenter study, on antibiotic selection, and clinical, antimicrobial, and economic endpoints, as compared with the standard of care (i.e., no AAL-fact-check tool).

Eligibility criteria

Qualifiers

Hospitalized patients

AAL for one or more beta-lactams

Disqualifiers

Age younger than 18

Previous enrolment in this study

Trial design

Treatments tested in this trial

  • EPR search

Treatment groups

3,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Universitaire Ziekenhuizen KU Leuven

Lead sponsor

Noorderhart Pelt

Collaborator

AZ Herentals

Collaborator

Heilig Hartziekenhuis, Mol

Collaborator

AZ Turnhout

Collaborator

Sint-Jozefskliniek Izegem

Collaborator